XOMA Royalty Corp (XOMA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Affitech research as-vabysmo | - | 5,817 | - | |
| Aptevo-ixinity | - | 253 | - | |
| Total income and revenues | 13,129 | 15,912 | 7,197 | |
| Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. includes royalty purchase agreement asset impairment | - | - | 14,000 | |
| Research and development | 69 | 1,293 | 817 | |
| General and administrative | 7,802 | 8,146 | 8,020 | |
| Amortization of intangible assets | 655 | 544 | - | |
| Total operating expenses | 8,526 | 9,983 | 22,837 | |
| Income (loss) from operations | 4,603 | 5,929 | -15,640 | |
| Interest expense | 3,236 | 3,467 | 3,493 | |
| Other income, net | 7,824 | -95 | 1,890 | |
| Net income | 9,191 | 2,367 | -17,243 | |
| Earnings per share, basic | 0.46 | 0.06 | -1.59 | |
| Earnings per share, diluted | 0.44 | 0.06 | -1.59 | |
| Weighted average number of shares outstanding, basic | 12,007,000 | 11,969,000 | 11,712,000 | |
| Weighted average number of shares outstanding, diluted | 17,761,000 | 17,781,000 | 11,712,000 | |